Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and the bet did not pay off.
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
Doeren Mayhew acquired CPA firm Dent Moses and its affiliate, Impact Technology Group, expanding its presence in the Southeast and adding to its technology service offering.
The American Institute of CPAs is asking the Treasury Department and the Internal Revenue Service for further guidance on the rules for deducting domestic research and development expenses in light of the changes under the One Big Beautiful Bill Act.
The Securities and Exchange Commission is making extensive changes in auditing and accounting as it continues to deregulate under the Trump administration.